StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)
Stock analysts at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th. View Our […]
Stock analysts at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th. View Our […]
